ECHELON-2: a large peripheral T-cell lymphoma trial
ECHELON-2: a large peripheral T-cell lymphoma trial
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL
Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia
Immunotherapy in older patients
Results from the Health ABC study on accelerated sarcopenia in older cancer patients
Young SIOG attendees and and the latest CDK inhibitors research in breast cancer
Brain metastases: therapeutic options
BRAF/MEK inhibition as adjuvant treatment in melanoma
The changing landscape of melanoma treatment